Catalyst Pharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Catalyst Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.02. The biopharmaceutical company had revenue of $30.21 million for the quarter, compared to the consensus estimate of $32.14 million. Catalyst Pharmaceuticals had a net margin of 60.11% and a trailing twelve-month return on equity of 27.81%.
View Catalyst Pharmaceuticals' earnings history.

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CPRX shares have increased by 61.4% and is now trading at $5.68.
View which stocks have been most impacted by COVID-19.

3 analysts have issued 1 year target prices for Catalyst Pharmaceuticals' stock. Their forecasts range from $5.50 to $11.00. On average, they expect Catalyst Pharmaceuticals' share price to reach $7.88 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Catalyst Pharmaceuticals include FibroGen (FGEN), ALX Oncology (ALXO), Prothena (PRTA), Morphic (MORF), Zentalis Pharmaceuticals (ZNTL), Nuvation Bio (NUVB), Centessa Pharmaceuticals (CNTA), Xencor (XNCR), Revance Therapeutics (RVNC), Deciphera Pharmaceuticals (DCPH), Ligand Pharmaceuticals (LGND), Organogenesis (ORGO), Atea Pharmaceuticals (AVIR), Amarin (AMRN) and Myovant Sciences (MYOV).
View all of CPRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.00%), Royce & Associates LP (3.14%), Prudential Financial Inc. (2.66%), Geode Capital Management LLC (1.71%), Goldman Sachs Group Inc. (1.38%) and LSV Asset Management (1.36%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals.

CPRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Man Group plc, AQR Capital Management LLC, D. E. Shaw & Co. Inc., Wedge Capital Management L L P NC, Schroder Investment Management Group, Credit Suisse AG, and JPMorgan Chase & Co..
View insider buying and selling activity for Catalyst Pharmaceuticals or view top insider-selling stocks.

CPRX stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP, Citigroup Inc., State Board of Administration of Florida Retirement System, BlackRock Inc., Dimensional Fund Advisors LP, Acadian Asset Management LLC, Rafferty Asset Management LLC, and Globeflex Capital L P. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, and Patrick J Mcenany.
View insider buying and selling activity for Catalyst Pharmaceuticals or or view top insider-buying stocks.

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $5.68.

Catalyst Pharmaceuticals has a market capitalization of $587.11 million and generates $119.07 million in revenue each year. The biopharmaceutical company earns $74.98 million in net income (profit) each year or $0.40 on an earnings per share basis.

Catalyst Pharmaceuticals employs 74 workers across the globe.

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]